BioSpace News Archive

ALK’s ( ALKB:DC / OMX: ALK B / AKBLF ) Board of Directors has approved the company’s 2023 annual report.

Spyre Therapeutics, Inc. today announced three abstracts co-written with Spyre’s research partner, Paragon Therapeutics, Inc., highlighting that the Company’s co-lead product candidates, SPY001 and SPY002, have been accepted for presentation as posters at the upcoming 19th Annual Congress of the European Crohn’s and Colitis Organisation.

Health Catalyst, Inc. (“Health Catalyst”, Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, will release its fourth quarter and full year 2023 operating results on Thursday, February 22, 2024, after market close.

Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update.

Quoin Pharmaceuticals Ltd. today announced it has filed U.S. and International patent applications for a novel combination product as a potential treatment of Netherton Syndrome.

Assembly Biosciences, Inc. today announced that it expects a 1-for-12 reverse stock split of its outstanding shares of common stock will be effective as of February 9, 2024.

Sensus Healthcare, Inc. announces that the U.S. Patent and Trademark Office has issued Patent No. 11,894,123 B2, titled “Radiotherapy Mobile and Wireless Device Workflow Management System.”.

Tenaya Therapeutics, Inc. today announced the pricing of its underwritten offering of 8,888,890 shares of its common stock at an offering price of $4.50 per share.

Leiden, The Netherlands, February 8, 2024: Pharming Group N.V. announces that Pharming’s management will participate in the following investor conferences in the month of February.

XNK Therapeutics AB announced that Johan Liwing, CEO, will present the company at the Redeye Regenerative Medicine/Cell Therapy event on February 14.